ZAI LAB LIMITED Depreciation
ZAI LAB LIMITED (ZLAB) reported Depreciation of $2.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- ZAI LAB LIMITED depreciation for the quarter ending 2026-06-30 was $2.40M, a 4.35% increase year-over-year.
- ZAI LAB LIMITED depreciation for the quarter ending 2026-03-31 was $2.30M, a 15.00% increase year-over-year.
- ZAI LAB LIMITED depreciation for the quarter ending 2025-12-31 was $2.40M, a 20.00% increase year-over-year.
- ZAI LAB LIMITED depreciation for the quarter ending 2025-09-30 was $2.40M, a 14.29% increase year-over-year.
- ZAI LAB LIMITED depreciation for fiscal 2025 was $9.10M, a 5.81% increase from fiscal 2024.
- ZAI LAB LIMITED depreciation for fiscal 2024 was $8.60M, a 2.38% increase from fiscal 2023.
- ZAI LAB LIMITED depreciation for fiscal 2023 was $8.40M, a 9.09% increase from fiscal 2022.
- ZAI LAB LIMITED depreciation for fiscal 2022 was $7.70M, a 28.33% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.40M 10-Q · filed 2026-08-06 | $4.70M 10-Q · filed 2026-08-06 | $7.10M derived: sum of 3 quarters · filed 2026-08-06 | $9.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.30M 10-Q · filed 2026-05-07 | $4.70M derived: sum of 2 quarters · filed 2026-05-07 | $7.10M derived: sum of 3 quarters · filed 2026-05-07 | $9.40M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.80M derived: sum of 2 quarters · filed 2026-02-26 | $7.10M derived: sum of 3 quarters · filed 2026-08-06 | $9.10M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $2.40M 10-Q · filed 2025-11-06 | $4.70M derived: sum of 2 quarters · filed 2026-08-06 | $6.70M 10-Q · filed 2025-11-06 | $8.70M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.30M 10-Q · filed 2026-08-06 | $4.30M 10-Q · filed 2026-08-06 | $6.30M derived: sum of 3 quarters · filed 2026-08-06 | $8.40M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-07 | $4.00M derived: sum of 2 quarters · filed 2026-05-07 | $6.10M derived: sum of 3 quarters · filed 2026-05-07 | $8.30M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.10M derived: sum of 2 quarters · filed 2026-02-26 | $6.30M derived: sum of 3 quarters · filed 2026-02-26 | $8.60M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $2.10M 10-Q · filed 2025-11-06 | $4.30M derived: sum of 2 quarters · filed 2025-11-06 | $6.60M 10-Q · filed 2025-11-06 | $8.80M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $2.20M 10-Q · filed 2025-08-07 | $4.40M 10-Q · filed 2025-08-07 | $6.70M derived: sum of 3 quarters · filed 2026-02-26 | $8.50M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $2.20M 10-Q · filed 2025-05-08 | $4.50M derived: sum of 2 quarters · filed 2026-02-26 | $6.30M derived: sum of 3 quarters · filed 2026-02-26 | $8.10M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.10M derived: sum of 2 quarters · filed 2026-02-26 | $5.90M derived: sum of 3 quarters · filed 2026-02-26 | $8.40M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $1.80M 10-Q · filed 2024-11-12 | $3.60M derived: sum of 2 quarters · filed 2024-11-12 | $6.10M 10-Q · filed 2024-11-12 | $8.10M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $1.80M 10-Q · filed 2024-08-06 | $4.30M 10-Q · filed 2024-08-06 | $6.30M derived: sum of 3 quarters · filed 2025-02-27 | $8.40M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $2.50M 10-Q · filed 2024-05-08 | $4.50M derived: sum of 2 quarters · filed 2025-02-27 | $6.60M derived: sum of 3 quarters · filed 2025-02-27 | $8.30M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.10M derived: sum of 2 quarters · filed 2025-02-27 | $5.80M derived: sum of 3 quarters · filed 2025-02-27 | $7.70M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $2.10M 10-Q · filed 2023-11-07 | $3.80M derived: sum of 2 quarters · filed 2023-11-07 | $5.70M 10-Q · filed 2023-11-07 | $7.40M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $1.70M 10-Q · filed 2023-08-07 | $3.60M 10-Q · filed 2023-08-07 | $5.30M derived: sum of 3 quarters · filed 2024-02-27 | $6.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-09 | $1.87M 10-Q · filed 2022-05-10 | $3.60M derived: sum of 2 quarters · filed 2024-02-27 | $5.10M derived: sum of 3 quarters · filed 2024-02-27 | $6.50M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.20M derived: sum of 2 quarters · filed 2024-02-27 | $4.60M derived: sum of 3 quarters · filed 2024-02-27 | $6.00M 10-K · filed 2024-02-27 | $5.99M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $1.50M 10-Q · filed 2022-11-09 | $1.51M 10-Q · filed 2021-11-09 | $2.90M derived: sum of 2 quarters · filed 2022-11-09 | $4.30M 10-Q · filed 2022-11-09 | $4.26M 10-Q · filed 2021-11-09 | $5.50M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $1.40M 10-Q · filed 2022-08-09 | $1.41M 10-Q · filed 2021-08-09 | $2.70M 10-Q · filed 2022-08-09 | $2.75M 10-Q · filed 2021-08-09 | $4.00M derived: sum of 3 quarters · filed 2023-03-01 | $5.07M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $1.34M 10-Q · filed 2022-05-10 | $2.60M derived: sum of 2 quarters · filed 2023-03-01 | $3.67M derived: sum of 3 quarters · filed 2023-03-01 | $4.63M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.33M derived: sum of 2 quarters · filed 2023-03-01 | $3.29M derived: sum of 3 quarters · filed 2023-03-01 | $4.30M 10-K · filed 2023-03-01 | $1.63M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $1.06M 10-Q · filed 2021-11-09 | $2.03M derived: sum of 2 quarters · filed 2021-11-09 | $3.04M 10-Q · filed 2021-11-09 | $4.16M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $968.00K 10-Q · filed 2021-08-09 | $1.97M 10-Q · filed 2021-08-09 | $3.10M derived: sum of 3 quarters · filed 2022-03-01 | $3.90M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $1.01M 10-Q · filed 2021-05-10 | $2.13M derived: sum of 2 quarters · filed 2022-03-01 | $2.93M derived: sum of 3 quarters · filed 2022-03-01 | |||||
| 2019-12-31 | $1.12M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $1.93M derived: sum of 2 quarters · filed 2022-03-01 | $3.37M 10-K · filed 2022-03-01 | |||||
| 2019-09-30 | $802.96K derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $2.25M 6-K · filed 2020-01-21 | ||||||
| 2019-06-30 | $1.45M 6-K · filed 2020-09-11 | |||||||
| 2018-12-31 | $3.18M derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $4.32M 10-K · filed 2021-03-01 | $1.63M 20-F · filed 2019-03-29 | |||||
| 2018-09-30 | $1.14M 6-K · filed 2020-01-21 | |||||||
| 2017-12-31 | $546.00K 20-F · filed 2020-04-29 | $545.71K 20-F · filed 2018-04-30 | ||||||
| 2016-12-31 | $198.22K 20-F · filed 2019-03-29 | |||||||
| 2015-12-31 | $125.77K 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |